News

Press Releases

  • January 10, 2023

    Genesis Axis Acquires Organochem to Grow the Preclinical Chemistry Services Portfolio.

    View
  • October 7, 2021

    Genesis Biotechnology Group Acquires BioBlocks to Grow the Preclinical Chemistry Services Portfolio of Genesis Drug Discovery & Development (GD3)

    View
  • September 16, 2021

    Genesis Drug Discovery & Development Appoints Anthony Rohr as Chief Operating Officer

    View
  • September 16, 2021

    Genesis Drug Discovery & Development Appoints Laura Sailor Veteran CRO Business Development Leader as Director of Business Development

    View
  • March 4, 2021

    Genesis Drug Discovery and Development acquires Integrated Analytical Solutions to add "off the shelf" PK profiling capabilities to its portfolio.

    View
  • January 6, 2021

    Genesis Drug Discovery and Development expands its presence in the clinical space by acquiring STATKING Clinical Services

    View
  • December 9, 2020

    Genesis Biotechnology Group announces second year of CRO relationship with Yale University

    View
  • August 5, 2020

    Genesis Biotechnology Group acquires Comparative Biosciences, Inc. (CBI) to add GLP Toxicology and Safety Pharmacology to its portfolio of Preclinical Services

    View
  • August 4, 2020

    Genesis Drug Discovery & Development (GD3) Announces Appointment of Anthony Rohr, as Chief Executive Officer of PharmOptima.

    View
  • November 19, 2019

    Genesis Biotechnology Group acquires NEDP to grow the Preclinical Chemistry services portfolio of Genesis Drug Discovery & Development

    View
  • June 18, 2019

    Genesis Drug Discovery & Development Expands Preclinical Contract Research Portfolio by Acquiring NexusPharma.

    View
  • January 1, 2016

    EPO Berlin-Buch GmbH announces strategic partnership for the American market: EPO starts strategic collaboration with NexusPharma to foster its market position in the USA

    View